Laser remains standard of DME therapy

Article

Combination therapy also showing promise

The International Diabetes Federation estimates that in the European countries of Austria, France, Germany, Italy, Portugal and Spain there are 22.1 million people currently living with diabetes, and the Center for Disease Control and Prevention estimates that 25.8 million Americans also have the disease. As the global population continues to age, there is increasing pressure for treatments that are both clinically effective and economically efficient. Advances in laser treatment protocols allow it to meet both of these criteria, and combined therapies are showing promise as well.

The evolution of laser photocoagulation

The packet of photons in each micropulse contains much less energy than a whole pulse. When the train of micropulses reaches the target tissue, thermal elevation and its diffusion from the impact zone are limited significantly. The result is that the sublethal treatment affects only a small collection of retinal epithelial cells and just the tips of the photoreceptors, as opposed to the large crater created with standard continuous-wave laser therapies. In essence, the visible burn has been eliminated.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.